CENTOGENE

[Available On-Demand]
Search General Info
Search Education
Search Partnering Companies
CENTOGENE is the global leader in providing molecular insights to accelerate the development of targeted treatments for patients with rare genetic diseases. The Company accomplishes this by using a multidimensional approach to analyze patient data and by harnessing its unsurpassed knowledge of rare diseases to help physicians more easily diagnose patients and biotech/pharma companies develop new treatment options.
CENTOGENE is also leveraging its expertise in providing precise medical diagnoses to address the urgent need facing our society as result of COVID-19. We have dedicated a significant amount of resources to developing a diagnostic that quickly and accurately identifies people who have COVID-19, so they can take the appropriate steps to protect themselves and their families. We have already made this diagnostic available in Germany and are working endlessly to help more societies return to the ‘new normal’ as quickly as possible.
Ticker:
CNTG
Exchange:
NASDAQ
Company Type:
Not Provided
Company Website:
Company HQ State:
Not Provided
Company HQ Country:
Germany
Year Founded:
2006
Main Therapeutic Focus:
Lead Product in Development:
CentoMetabolic®
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided
Speaker
photo
Chief Executive Officer
CENTOGENE